Nanobiotix S.A.
NANO.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 0.18 | -0.10 | 2.48 |
| FCF Yield | -14.29% | -5.25% | -30.21% | -12.30% |
| EV / EBITDA | -2.34 | -7.29 | -2.62 | -4.57 |
| Quality | ||||
| ROIC | -510.92% | -54.77% | -178.54% | -68.38% |
| Gross Margin | 100.00% | 100.00% | 68.59% | 26,470.00% |
| Cash Conversion Ratio | 0.29 | 0.31 | 0.67 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | – | 1,343.18% | 357.12% | -47.22% |
| Free Cash Flow Growth | -59.21% | 66.38% | -22.01% | -10.20% |
| Safety | ||||
| Net Debt / EBITDA | -0.02 | 0.82 | -0.27 | 0.80 |
| Interest Coverage | -8.46 | -3.35 | -8.65 | -78.36 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -268.35 | 115.30 | -755.89 | 142,421.02 |